Cognition and HRQoL in Adults With Highly-active RMS in Year 3 and 4 After Initial Mavenclad® Dose (CLARIFY MS Extension)

Clinical trial NCT04776213 · COMPLETED

Trial details

NCT number: NCT04776213
Sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Status: COMPLETED
Phase: Phase 4
Study type: INTERVENTIONAL

Multiple Sclerosis

Start date: 2021-02-23
Primary completion: 2023-06-20
Enrollment: 280

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.